GENEVA — The World Health Organization (WHO) has announced the immediate allocation of 70,000 doses of Merck's Ervebo Ebola vaccine to the Democratic Republic of the Congo (DRC) to help stem an escalating viral outbreak.
According to the WHO and international health coordination groups, the shipment follows an urgent request submitted by the government in Kinshasa to address the fast-growing transmission of the virus. While the Ervebo vaccine was originally licensed to target the Zaire ebolavirus strain, health officials note that current deployments will target the spreading Bundibugyo strain. Out of the total allocation, 20,000 doses are designated for a formal clinical trial to evaluate cross-protection effectiveness against the strain, while the remaining 50,000 doses are prioritized for frontline healthcare workers.
Public health experts emphasize that while early data from animal studies suggest potential cross-protection, ongoing clinical evaluations remain critical to establishing formal policy guidelines. International agencies continue to coordinate logistics to support local medical teams operating in affected regions, with initial shipments already arriving on the ground.
.png)
The opinions posted here do not belong to 🔰www.indiansdaily.com. The author is solely responsible for the opinions.
As per the IT policy of the Central Government, insults against an individual, community, religion or country, defamatory and inflammatory remarks, obscene and vulgar language are punishable offenses. Legal action will be taken for such expressions of opinion.